You are here

Yale Study: Pulmonary Embolism Treatment Widely Used Despite High Cost and Uncertain Benefit

Authors question value of IVC filters in older adults

Despite being costly and of little proven benefit, a procedure for treating pulmonary embolism with blood clot filters is routinely used in older adults, Yale School of Medicine researchers have found. Published in the Journal of the American College of Cardiology, the study also showed that the utilization rates of inferior vena caval (IVC) filters varied widely across different regions of the United States.

IVC filters are aimed at obstructing the path of blood clots to prevent pulmonary embolism.

“The best use of the IVC filter technology remains uncertain, but this procedure with very narrow indications is being performed in almost one in six patients,” said lead investigator Dr. Behnood Bikdeli. “Further research will help identify the subgroups of people that will benefit most from this procedure.”

The researchers studied 550,000 Medicare fee-for-service beneficiaries 65 years of age or older who were hospitalized for pulmonary embolism between 1999 and 2010. The team found frequent and increasing use of IVC filters in patients with pulmonary embolism over time, even as death from pulmonary embolism decreased during the same period, regardless of whether IVC filters were used. They also found that out of the 550,000 older adults with pulmonary embolism, 94,000 (17%) received an IVC filter.

Bikdeli said that IVC filters might be reasonable for a select group of patients, but not for such widespread use.

“Contrary to some common beliefs, they are simply not a bulletproof vest against pulmonary embolism,” he said. “Given that this procedure is not devoid of costs or complications, we really need good comparative-effectiveness studies to determine which patients may benefit from IVC filters.”

Sources: Yale University; March 22, 2016; and JACC; March 8, 2016.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs